Supernus Stock Plunges 30% to a 52-Week Low on Its First Day as a Merged Company

Supernus, Inc. (Nasdaq: SUPN) fell about 30% on Tuesday, November 3, 2026 — its very first day of trading as the newly merged Supernus–Indivior company. The stock traded as low as $29.00, a new 52-week low, and was last shown at $29.31, down 30.08% as of 3:09 p.m. Eastern, on volume of about 4.03 million shares — roughly five times its average volume of about 796,000 shares.

What happened

Supernus Pharmaceuticals and Indivior Pharmaceuticals completed their merger on November 2, 2026, creating Supernus, Inc., a diversified central nervous system (CNS) biopharmaceutical company. The combined company began trading on the Nasdaq Global Market under the ticker SUPN on November 3, replacing the prior Indivior listing, with headquarters retained in Rockville, Maryland.

Under the merger terms, Supernus Pharmaceuticals stockholders received 1.5401 shares of Indivior common stock for each Supernus share they held. Former Indivior stockholders own about 56.5% of the combined company, and former Supernus stockholders own about 43.5%, on a fully diluted basis.

Why the stock is blowing up — downward

First-day trading in a merged company often involves a mechanical repricing, and that is part of the story here. The share count, shareholder mix and reference price all changed at the close, so Tuesday's percentage move is not directly comparable to an ordinary trading day for the old Supernus stock, which had previously closed at $41.92.

Investors also had new debt to weigh. Stockholders of Indivior immediately before the closing receive a one-time special cash dividend of $1.0 billion in total. The companies financed that dividend through a $650 million term loan facility provided by Citibank, with the remaining $350 million funded from existing cash resources of the combined business. Taking on debt to fund a large cash payout, alongside integration uncertainty, gave traders reasons to revalue the combined company lower on day one.

The combined company in brief

The merger brings together Supernus's neurology and psychiatry treatments with Indivior's addiction medicine business. The combined company has an 11-product commercial portfolio spanning opioid use disorder, psychiatry and neurology. It has identified five core products as its principal growth drivers: SUBLOCADE, Qelbree, GOCOVRI, ONAPGO and ZURZUVAE.

Khattar, previously chief executive of Supernus Pharmaceuticals, leads the combined company. Tony Kingsley, previously a director at Indivior, serves as chairman of an eight-member board that includes four directors from each legacy company. Management has targeted about $125 million in annual cost synergies from the combination. The companies did not provide updated combined revenue or earnings projections in their closing announcement.

Why it matters beyond one stock

The plunge is a reminder that merger completions can be volatile even when a deal was announced months earlier — this one was first announced in August 2026. Until the combined company reports results as a single business, investors have limited visibility on how the two product portfolios, the new debt load and the promised cost savings fit together. That uncertainty, rather than a new clinical or regulatory setback, is what Tuesday's trading reflected. No clinical failure or regulatory rejection was reported as the cause of the fall.

What's next

The next checkpoints are execution items, not headlines: progress toward the targeted $125 million in annual cost synergies, how the combined company handles the new $650 million term loan, and its first earnings report as a merged business. Until those arrive, the stock is likely to remain sensitive to any update on integration and on sales of its five core growth products.

This article reports what happened and why markets reacted. It is not financial advice, and it does not recommend buying, selling or holding any security.

Sources

FAQ

Why did Supernus stock fall about 30% on November 3, 2026?

It was the first trading day for the combined Supernus–Indivior company under the SUPN ticker. Traders repriced the new share structure, the $650 million loan taken on to help fund a $1 billion special dividend, and integration uncertainty.

When did the Supernus–Indivior merger close?

The merger was completed on November 2, 2026, and the combined company, Supernus, Inc., began trading on Nasdaq under SUPN on November 3, 2026.

What did Supernus shareholders receive in the merger?

They received 1.5401 shares of Indivior common stock for each Supernus share held. Former Indivior holders own about 56.5% of the combined company and former Supernus holders about 43.5%.

What are the combined company's main products?

Its 11-product portfolio spans opioid use disorder, psychiatry and neurology, with five core growth drivers named by the company: SUBLOCADE, Qelbree, GOCOVRI, ONAPGO and ZURZUVAE.